Komboglyze

saxagliptin / metformin hydrochloride

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Komboglyze. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Komboglyze.

What is Komboglyze?

Komboglyze is a medicine that contains the active substances saxagliptin and metformin. It is available as tablets (2.5 mg / 850 mg or 2.5 mg / 1,000 mg).

What is Komboglyze used for?

Komboglyze is used in adults with type-2 diabetes to improve the control of blood glucose (sugar) levels. It is used in addition to diet and exercise in the following ways:

  • in patients whose blood glucose levels are not adequately controlled by metformin alone;
  • in patients already being treated with saxagliptin and metformin as separate tablets;
  • in combination with insulin in patients whose blood glucose is not adequately controlled by insulin and metformin alone;
  • in combination with a sulphonylurea in patients whose blood glucose is not adequately controlled with the highest possible doses of a combined metformin and sulphonylurea treatment.

The medicine can only be obtained with a prescription.

How is Komboglyze used?

Komboglyze is taken as one tablet twice a day at mealtimes. The strength of tablet to use depends on the dose of the other antidiabetes medicines that the patient was taking before. 

Patients not adequately controlled on metformin alone who start taking Komboglyze should continue to receive the same dose of metformin they were previously taking. 

Patients already adequately controlled with saxagliptin and metformin as separate tablets who switch to Komboglyze should use the tablet containing the same component doses. 

If Komboglyze is taken with insulin or a sulphonylurea, the dose of insulin or the sulphonylurea may need to be lowered, to reduce the risk of hypoglycaemia (low blood sugar levels).

How does Komboglyze work?

Type-2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. The active substances in Komboglyze, saxagliptin and metformin, each have a different mode of action to help reduce blood glucose levels and control type-2 diabetes.

Saxagliptin is a dipeptidyl-peptidase-4 (DPP4) inhibitor. It works by blocking the breakdown of ‘incretin’ hormones in the body. These hormones are released after a meal and stimulate the pancreas to produce insulin. By increasing levels of incretin hormones in the blood, saxagliptin stimulates the pancreas to produce more insulin when blood glucose levels are high. Saxagliptin does not work when the blood glucose is low. Saxagliptin also reduces the amount of glucose made by the liver, by increasing insulin levels and decreasing the levels of the hormone glucagon. Saxagliptin has been authorised in the European Union (EU) as Onglyza since 2009.

The active substance metformin works mainly by blocking glucose production and reducing its absorption in the gut. Metformin has been available in the EU since the 1950s.

As a result of the action of both active substances, blood glucose levels are reduced and this helps to control type-2 diabetes.

How has Komboglyze been studied?

One study examined the effects of saxagliptin added to metformin in 160 patients. Another five looked at the effects of saxagliptin alone or in combination with metformin, compared either with placebo (a dummy treatment) or another medicine (a sulphonylurea or sitagliptin) in over 4,000 patients. A study in 455 patients compared saxagliptin with placebo when added to insulin, with or without metformin and the eighth study (in 257 patients) compared saxagliptin with placebo when added to metformin and a sulphonylurea.

The main measure of effectiveness in all the studies was the change in the levels of glycosylated haemoglobin (HbA1c), which is the percentage of haemoglobin in the blood that has glucose attached. HbA1c gives an indication of how well the blood glucose is controlled.

The company also presented the results of a study in 32 healthy people looking at the levels of saxagliptin in the blood when saxagliptin is taken at 2.5 mg twice daily compared with when it is taken at 5 mg once daily.

What benefit has Komboglyze shown during the studies?

Combinations of saxagliptin and metformin as used in Komboglyze were shown to be effective in lowering patients’ blood glucose.

In the study of 160 patients, patients taking saxagliptin with metformin had a reduction of 0.6% in their HbA1c levels, compared with a reduction of 0.2% in patients taking placebo with metformin. The five studies on the effects of saxagliptin alone or in combination with metformin also showed that adding saxagliptin to metformin was effective in lowering HbA1c levels.

In the study where saxagliptin was taken in addition to insulin (with or without metformin), HbA1c levels fell by around 0.7%, compared with a decrease of around 0.3% in patients who took placebo with insulin.

In the eighth study, a reduction of 0.7% was seen in patients who received triple therapy with saxagliptin, metformin and a sulphonylurea compared with a reduction of 0.1% in patients who were given placebo in place of saxagliptin.

The study in healthy people showed that when saxagliptin is taken at 2.5 mg twice daily it produces the same levels of active substance in the blood over a 24-hour period as when it is taken at 5 mg once daily.

What is the risk associated with Komboglyze?

The most common side effects seen with saxagliptin used together with metformin (seen in between 1 and 10 patients in 100) are upper respiratory infection (cold), urinary-tract infection (infection of the structures that carry urine such as the bladder), gastroenteritis (diarrhoea and vomiting), sinusitis (inflammation of the sinuses), nasopharyngitis (inflammation of the nose and throat), headache and vomiting. For the full list of all side effects reported with saxagliptin and metformin, see the package leaflet.

Komboglyze must not be used in patients who are hypersensitive (allergic) to saxagliptin and metformin or any of the other ingredients, or who have ever had a serious allergic reaction to any DPP4 inhibitor. It must not be used in patients with diabetic ketoacidosis or diabetic precoma (a dangerous condition that can occur in diabetes), patients with moderately to severely reduced kidney function or with acute (sudden) conditions which can affect kidney function, patients with diseases which can cause tissue hypoxia (where the tissue is deprived of adequate oxygen supply) such as heart failure or difficulty breathing, patients with reduced liver function, alcohol poisoning or alcoholism. It must not be used in women who are breastfeeding.

Why has Komboglyze been approved?

The CHMP concluded that Komboglyze helps to reduce blood glucose levels in patients whose blood glucose levels are not adequately controlled by metformin alone, while the combination of saxagliptin and metformin in one tablet may help patients who already take both to follow their treatment correctly. The CHMP also noted that the combination does not cause any unexpected side effects. The Committee therefore concluded that the benefits of Komboglyze outweigh its risks and recommended that it be given marketing authorisation.

Other information about Komboglyze

The European Commission granted a marketing authorisation valid throughout the European Union for Komboglyze on 24 November 2011.

For more information about treatment with Komboglyze, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Komboglyze : EPAR - Summary for the public BG = bălgarski 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public ES = español 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public CS = čeština 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public DA = dansk 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public DE = Deutsch 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public ET = eesti keel 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public EL = elliniká 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public EN = English 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public FR = français 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public IT = italiano 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public LV = latviešu valoda 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public LT = lietuvių kalba 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public HU = magyar 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public MT = Malti 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public NL = Nederlands 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public PL = polski 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public PT = português 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public RO = română 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public SK = slovenčina 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public SL = slovenščina 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public FI = suomi 16/12/2011 14/06/2013
Komboglyze : EPAR - Summary for the public SV = svenska 16/12/2011 14/06/2013

This EPAR was last updated on 24/11/2015 .

Authorisation details

Product details

Product details for Komboglyze
NameKomboglyze
Agency product numberEMEA/H/C/002059
Active substance

metformin hydrochloride / saxagliptin hydrochloride

International non-proprietary name (INN) or common name

saxagliptin / metformin hydrochloride

Therapeutic area Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code A10BD10

Publication details

Publication details for Komboglyze
Marketing-authorisation holder

AstraZeneca AB 

Revision9
Date of issue of marketing authorisation valid throughout the European Union24/11/2011

Contact address:

AstraZeneca AB
151 85 Södertälje
Sweden

Product information

Product information

01/10/2015  Komboglyze -EMEA/H/C/002059 -WS/0810/G

Name Language First published Last updated
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015
Komboglyze : EPAR - Product Information SV = svenska 16/12/2011 24/11/2015

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012
Komboglyze : EPAR - All Authorised presentations SV = svenska 16/12/2011 12/06/2012

Pharmacotherapeutic group

Drugs used in diabetes, combinations of oral blood-glucose-lowering drugs

Therapeutic indication

Komboglyze is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type-2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets.

Komboglyze is also indicated in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type-2 diabetes mellitus when insulin and metformin alone do not provide adequate glycaemic control.

Assessment History

Changes since initial authorisation of medicine

Initial marketing-authorisation documents

Name Language First published Last updated
Komboglyze : EPAR - Public assessment report SV = svenska 16/12/2011  
CHMP summary of positive opinion for Komboglyze SV = svenska 23/09/2011